Does 'NICE blight' exist, and if so, why?

PharmacoEconomics

Volumn 26, Issue 12, 2008, Pages 987-989

  Haycox, Alan ^a  

^a UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

Cost effectiveness; Formularies; Health policy

Indexed keywords

RITUXIMAB;

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; EDITORIAL; HEALTH CARE ORGANIZATION; HUMAN; MARKETING; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROCESS CONTROL; PROCESS OPTIMIZATION; UNITED KINGDOM;

DECISION MAKING, ORGANIZATIONAL; GREAT BRITAIN; NATIONAL HEALTH PROGRAMS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TIME FACTORS;

EID: 56549089502     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/0019053-200826120-00002     Document Type: Editorial

References (1)

1. Barham L. Single technology appraisals by NICE: are they delivering faster guidance to the NHS? Pharmacoeconomics 2008; 26 (12): 1037-43